Jinlin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jinlin Zhang has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Cheng Tang
Department of Cardiology, Wuhan Asian Heart Hospital, Wuhan, China
9 shared publicationsXi Su
Department of Cardiology, Wuhan Asian Heart Hospital, Hubei Province, Wuhan City, China
6 shared publicationsYonghua Zhang
Department of Cardiology, Wuhan Asian Heart Hospital, Wuhan, China
5 shared publicationsAnquan Zhao
Boston Scientific China, Shanghai, China
4 shared publicationsChenggang Deng
Department of Cardiology, Wuhan Asia Heart Hospital, Wuhan, China
4 shared publicationsXi Li
Department of Cardiology, Wuhan Asia General Hospital, Wuhan, Hubei, China
4 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (46) , 110992
Successful Guidewire-Guided Ethanol Ablation for PVCs Originating From Epicardial Anterior Interventricular Groove Adjacent to LAD
- 16 October 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (46) , 110992
Open AccessSuccessful Guidewire-Guided Ethanol Ablation for PVCs Originating From Epicardial Anterior Interventricular Groove Adjacent to LAD
- 10 July 2026
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 69 (9) , 2881-2889
Catheter ablation of ventricular arrhythmias originating from right ventricular posterior papillary muscle-false tendon complexZhang et al. Right ventricular posterior papillary muscle-false tendon complex
Background and aims Posterior papillary muscle (PPM) and false tendons (FTs) in the right ventricle (RV) may act as a potential source of ventricular arrhythmias(VAs). We aimed to systematically describe the electrophysiological characteristics and the outcome of radiofrequency catheter ablation (RFCA) of VAs originating from the RV PPM -FT complex. Methods From a total of 2184 patients with VAs who underwent catheter ablation, 12 patients (0.55%) with VAs associated with RV PPM-FTs complex were enrolled in the study. Activation mapping and pace mapping were performed to localize the origin of VAs. Intracardiac echocardiography (ICE) was used in all patients to directly visualize the PPM and the FTs. We chose 12 patients with VAs originating from the RV moderate band (MB) as the control group. Conclusions In contrast to the MB group, the QRS duration, the R wave duration and the RS interval of lead V1 of the study group was longer. The negative component in inferior leads (II, III, aVF) of the study group was deeper than the MB group. The PVCs in the study group were successfully eliminated by ablation in all patients. The target sites were confirmed to be related to the RV PPM and FTs complex. A pre-systolic potential was observed preceding local ventricular activation in seven patients.
- 10 July 2026
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 69 (9) , 2881-2889
Catheter ablation of ventricular arrhythmias originating from right ventricular posterior papillary muscle-false tendon complexZhang et al. Right ventricular posterior papillary muscle-false tendon complex
Background and aims Posterior papillary muscle (PPM) and false tendons (FTs) in the right ventricle (RV) may act as a potential source of ventricular arrhythmias(VAs). We aimed to systematically describe the electrophysiological characteristics and the outcome of radiofrequency catheter ablation (RFCA) of VAs originating from the RV PPM -FT complex. Methods From a total of 2184 patients with VAs who underwent catheter ablation, 12 patients (0.55%) with VAs associated with RV PPM-FTs complex were enrolled in the study. Activation mapping and pace mapping were performed to localize the origin of VAs. Intracardiac echocardiography (ICE) was used in all patients to directly visualize the PPM and the FTs. We chose 12 patients with VAs originating from the RV moderate band (MB) as the control group. Conclusions In contrast to the MB group, the QRS duration, the R wave duration and the RS interval of lead V1 of the study group was longer. The negative component in inferior leads (II, III, aVF) of the study group was deeper than the MB group. The PVCs in the study group were successfully eliminated by ablation in all patients. The target sites were confirmed to be related to the RV PPM and FTs complex. A pre-systolic potential was observed preceding local ventricular activation in seven patients.
- Open Access
- 31 March 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (4)
A Successful Treatment of Ganglionated Plexus Ablation for Vagally Mediated Sleep‐Related Advanced Atrioventricular Block
We report a case of a 41‐year‐old man with recurrent nocturnal ventricular asystole secondary to advanced atrioventricular (AV) block, which was successfully treated with ganglionated plexus (GP) ablation based on the presumption of excessive vagal tone. This approach may offer a potential alternative for vagally mediated nocturnal AV block in selected young patients who decline pacemaker implantation.
- 31 March 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (4)
Open AccessA Successful Treatment of Ganglionated Plexus Ablation for Vagally Mediated Sleep‐Related Advanced Atrioventricular Block
We report a case of a 41‐year‐old man with recurrent nocturnal ventricular asystole secondary to advanced atrioventricular (AV) block, which was successfully treated with ganglionated plexus (GP) ablation based on the presumption of excessive vagal tone. This approach may offer a potential alternative for vagally mediated nocturnal AV block in selected young patients who decline pacemaker implantation.
- Open Access
- 3 November 2025
- Published by Wiley
A successful treatment of ganglionated plexus ablation for vagally mediated sleep-related advanced atrioventricular block
- 3 November 2025
- Published by Wiley
Open AccessA successful treatment of ganglionated plexus ablation for vagally mediated sleep-related advanced atrioventricular block
- Open Access
- 14 October 2025
- Published by Wiley
A successful treatment of ganglionated plexus ablation for vagally mediated sleep-related advanced atrioventricular block
Background Sleep-related bradyarrhythmia is often overlooked due to the absence of symptoms and are now mostly believed to be related to excessive vagal nerve tension. The choice of treatment still remains controversial. Ganglionated plexus (GP) ablation, as an experimental therapeutic approach, could be effective for some cases. Case summary We report a case of 41-year-old male with recurrent nocturnal ventricular asystole up to 10.1 seconds related to advanced atrioventricular block, in whom sleep apnea syndrome was excluded. Echocardiography, thyroid function test levels, coronary angiography and transesophageal electrophysiological test were normal. Considering that this significant nocturnal bradyarrhythmia is associated with increased vagal tone and decreased sympathetic activity, and the patient refused pacemaker implantation, we proceeded with GP ablation in the left atrial for the patient. After ablation, the patient’s nocturnal advanced atrioventricular block completely disappeared. Holter monitoring revealed heart rate variability analysis data consistent with successful vagal plexus ablation. Conclusion It seems like GP ablation is a safe and effective treatment for functional sleep-related bradyarrhythmia. Currently, we found 2 cases on nocturnal bradyarrhythmia from all relevant literatures, among which vagal ganglion ablation was successfully performed with favorable therapeutic effects. The case we report now may be the third one. Interestingly, the three cases that opted for GP ablation also differed in the selection of ablation sites. All three cases achieved significant therapeutic effects after ablation, and the selection of ablation methods needs further investigation. Further research is needed to elucidate the pathophysiological mechanisms underlying this autonomic disorder, and long-term follow-up is required to evaluate its sustained therapeutic efficacy.
- 14 October 2025
- Published by Wiley
Open AccessA successful treatment of ganglionated plexus ablation for vagally mediated sleep-related advanced atrioventricular block
Background Sleep-related bradyarrhythmia is often overlooked due to the absence of symptoms and are now mostly believed to be related to excessive vagal nerve tension. The choice of treatment still remains controversial. Ganglionated plexus (GP) ablation, as an experimental therapeutic approach, could be effective for some cases. Case summary We report a case of 41-year-old male with recurrent nocturnal ventricular asystole up to 10.1 seconds related to advanced atrioventricular block, in whom sleep apnea syndrome was excluded. Echocardiography, thyroid function test levels, coronary angiography and transesophageal electrophysiological test were normal. Considering that this significant nocturnal bradyarrhythmia is associated with increased vagal tone and decreased sympathetic activity, and the patient refused pacemaker implantation, we proceeded with GP ablation in the left atrial for the patient. After ablation, the patient’s nocturnal advanced atrioventricular block completely disappeared. Holter monitoring revealed heart rate variability analysis data consistent with successful vagal plexus ablation. Conclusion It seems like GP ablation is a safe and effective treatment for functional sleep-related bradyarrhythmia. Currently, we found 2 cases on nocturnal bradyarrhythmia from all relevant literatures, among which vagal ganglion ablation was successfully performed with favorable therapeutic effects. The case we report now may be the third one. Interestingly, the three cases that opted for GP ablation also differed in the selection of ablation sites. All three cases achieved significant therapeutic effects after ablation, and the selection of ablation methods needs further investigation. Further research is needed to elucidate the pathophysiological mechanisms underlying this autonomic disorder, and long-term follow-up is required to evaluate its sustained therapeutic efficacy.
- Open Access
- 22 April 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1556222
Female sex is an independent risk factor for recurrence after ethanol Marshall bundle elimination in atrial fibrillation ablation
Background: Atrial fibrillation (AF) exhibits gender disparities in prevalence, complications, pharmacological management, and ablation efficacy. Ethanol infusion of the vein of Marshall (EIVOM) is promising for enhancing AF ablation success rate, yet sex differences of EIVOM are lacking evidence.Method: This was a non-randomized, single-center, retrospective observational study. Patients with AF received stepwise ablations composed of EIVOM, pulmonary vein isolation, and linear ablation. The primary endpoint was defined as the recurrence of atrial tachycardia over 30 s. Propensity score matching (PSM) was performed to reduce selection bias.Results: From April 2020 to May 2022, 432 patients were included, comprising 288 male patients and 144 female patients. Compared with the male patients, the female patients were older, with worse heart function class. EIVOM success rate was significantly lower in the female patients compared with the male patients (86.1% vs. 93.4%). No significant differences in major procedural complications were observed between the male and female patients. During a median follow-up of 12 months, the female patients had significantly higher AF recurrence. Multivariate Cox regression analysis showed that female sex, body mass index 47 mm, and complex fractionated atrial electrogram ablation are independent risk factors for AF recurrence. After PSM, the AF recurrence rate remained statistically higher in the female patients compared with the male patients.Conclusion: Compared with the male patients, the female patients were older, more symptomatic, and had worse heart function. The female patients had significantly higher AF recurrence after EIVOM combined with catheter ablation.
- 22 April 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1556222
Open AccessFemale sex is an independent risk factor for recurrence after ethanol Marshall bundle elimination in atrial fibrillation ablation
Background: Atrial fibrillation (AF) exhibits gender disparities in prevalence, complications, pharmacological management, and ablation efficacy. Ethanol infusion of the vein of Marshall (EIVOM) is promising for enhancing AF ablation success rate, yet sex differences of EIVOM are lacking evidence.Method: This was a non-randomized, single-center, retrospective observational study. Patients with AF received stepwise ablations composed of EIVOM, pulmonary vein isolation, and linear ablation. The primary endpoint was defined as the recurrence of atrial tachycardia over 30 s. Propensity score matching (PSM) was performed to reduce selection bias.Results: From April 2020 to May 2022, 432 patients were included, comprising 288 male patients and 144 female patients. Compared with the male patients, the female patients were older, with worse heart function class. EIVOM success rate was significantly lower in the female patients compared with the male patients (86.1% vs. 93.4%). No significant differences in major procedural complications were observed between the male and female patients. During a median follow-up of 12 months, the female patients had significantly higher AF recurrence. Multivariate Cox regression analysis showed that female sex, body mass index 47 mm, and complex fractionated atrial electrogram ablation are independent risk factors for AF recurrence. After PSM, the AF recurrence rate remained statistically higher in the female patients compared with the male patients.Conclusion: Compared with the male patients, the female patients were older, more symptomatic, and had worse heart function. The female patients had significantly higher AF recurrence after EIVOM combined with catheter ablation.
- Open Access
- 25 November 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1486621
Ethanol marshall bundle elimination, pulmonary vein isolation, and linear ablation for atrial fibrillation with or without heart failure
Background: In medical practice, atrial fibrillation (AF) is intricately associated with heart failure (HF). Currently, ethanol infusion of vein of Marshall (EIVOM) for AF ablation in HF patients remains significantly limited.Method: This was a non-randomized, single-center, retrospective observational study. AF patients received 4-step ablation composed of EIVOM, pulmonary vein isolation (PVI) and linear ablation. The primary composite endpoint was defined as recurrence of atrial tachycardia over 30 s. Propensity score matching (PSM) was performed to reduce selection bias.Results: From April 2020 to May 2022, 362 patients were included, comprising of 182 HF patients and 180 non-HF patients. EIVOM success rate was lower in HF patients than non-HF patients (86.8% vs. 93.9%). Cardiac effusion was more common in HF patients (44.0% vs. 37.2%), and 2 cases of atrial-esophageal fistula were observed in the HF group. During a median follow-up of 12 months, no significant difference in the primary endpoint was observed between HF and non-HF group. Different HF subgroups had similar AF recurrence. After PSM, AF recurrence rate remained statistically equivalent between the HF and non-HF groups.Conclusion: EVIOM combining catheter ablation can be completed with comparable success rate in AF patients with or without HF. However, peri-procedural safety is a concern for HF patients undergoing EIVOM combing AF catheter ablation. During the follow-up, HF status before ablation is not related with increased AF recurrence.
- 25 November 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1486621
Open AccessEthanol marshall bundle elimination, pulmonary vein isolation, and linear ablation for atrial fibrillation with or without heart failure
Background: In medical practice, atrial fibrillation (AF) is intricately associated with heart failure (HF). Currently, ethanol infusion of vein of Marshall (EIVOM) for AF ablation in HF patients remains significantly limited.Method: This was a non-randomized, single-center, retrospective observational study. AF patients received 4-step ablation composed of EIVOM, pulmonary vein isolation (PVI) and linear ablation. The primary composite endpoint was defined as recurrence of atrial tachycardia over 30 s. Propensity score matching (PSM) was performed to reduce selection bias.Results: From April 2020 to May 2022, 362 patients were included, comprising of 182 HF patients and 180 non-HF patients. EIVOM success rate was lower in HF patients than non-HF patients (86.8% vs. 93.9%). Cardiac effusion was more common in HF patients (44.0% vs. 37.2%), and 2 cases of atrial-esophageal fistula were observed in the HF group. During a median follow-up of 12 months, no significant difference in the primary endpoint was observed between HF and non-HF group. Different HF subgroups had similar AF recurrence. After PSM, AF recurrence rate remained statistically equivalent between the HF and non-HF groups.Conclusion: EVIOM combining catheter ablation can be completed with comparable success rate in AF patients with or without HF. However, peri-procedural safety is a concern for HF patients undergoing EIVOM combing AF catheter ablation. During the follow-up, HF status before ablation is not related with increased AF recurrence.
- 28 August 2024
- Published by Elsevier in Heart Rhythm
- Vol. 22 (5) , 1159-1169
Activation patterns and electrophysiologic characteristics of Marshall bundle–related left atrial tachycardias after atrial fibrillation ablation
- 28 August 2024
- Published by Elsevier in Heart Rhythm
- Vol. 22 (5) , 1159-1169
Activation patterns and electrophysiologic characteristics of Marshall bundle–related left atrial tachycardias after atrial fibrillation ablation
- 9 April 2024
- Published by Elsevier in Heart Rhythm
- Vol. 21 (10) , 1853-1866
Electrophysiologic mechanism and ablation strategy for macroreentrant biatrial tachycardias after Cox-maze procedures
- 9 April 2024
- Published by Elsevier in Heart Rhythm
- Vol. 21 (10) , 1853-1866
Electrophysiologic mechanism and ablation strategy for macroreentrant biatrial tachycardias after Cox-maze procedures
- Open Access
- 7 December 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1276317
Efficacy and safety of the vein of Marshall ethanol infusion with radiofrequency catheter ablation for the treatment of persistent atrial fibrillation in elderly patients
Background: Increasing age is a significant risk factor for atrial fibrillation (AF) recurrence after catheter ablation (CA). We accomplished this study to evaluate the efficacy and safety of the vein of Marshall (VOM) ethanol infusion (VOM-EI) with CA in elderly patients with persistent AF (PsAF).Methods: This retrospective observational study included 360 consecutive adult patients with PsAF, of which 141 were in the Elder group (age ≥65 years) and 219 were in the Younger group (age <65 years), who underwent the VOM-EI and radiofrequency CA (RFCA) between May 2020 and April 2022. The efficacy endpoint was no recurrence of AF within one year after CA.Results: The VOM-EI was successfully performed in 90.8% of patients from the Elder and 88.6% from the Younger group. All patients achieved PVI; 97.9% of patients from the Elder and 98.6% from the Younger group reached LA roof block, and 93.6% of patients from the Elder and 95.9% from the Younger group achieved MI block. There was no significant difference in 1-year survival without recurrence of AF between the two groups (83.0% and 84.5%, respectively). The incidence of complications within 30 days after the procedure from the two groups was low and did not differ significantly.Conclusion: The VOM-EI combined with RFCA proved to be an effective and safe strategy for treating PsAF in elderly and younger patients.
- 7 December 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1276317
Open AccessEfficacy and safety of the vein of Marshall ethanol infusion with radiofrequency catheter ablation for the treatment of persistent atrial fibrillation in elderly patients
Background: Increasing age is a significant risk factor for atrial fibrillation (AF) recurrence after catheter ablation (CA). We accomplished this study to evaluate the efficacy and safety of the vein of Marshall (VOM) ethanol infusion (VOM-EI) with CA in elderly patients with persistent AF (PsAF).Methods: This retrospective observational study included 360 consecutive adult patients with PsAF, of which 141 were in the Elder group (age ≥65 years) and 219 were in the Younger group (age <65 years), who underwent the VOM-EI and radiofrequency CA (RFCA) between May 2020 and April 2022. The efficacy endpoint was no recurrence of AF within one year after CA.Results: The VOM-EI was successfully performed in 90.8% of patients from the Elder and 88.6% from the Younger group. All patients achieved PVI; 97.9% of patients from the Elder and 98.6% from the Younger group reached LA roof block, and 93.6% of patients from the Elder and 95.9% from the Younger group achieved MI block. There was no significant difference in 1-year survival without recurrence of AF between the two groups (83.0% and 84.5%, respectively). The incidence of complications within 30 days after the procedure from the two groups was low and did not differ significantly.Conclusion: The VOM-EI combined with RFCA proved to be an effective and safe strategy for treating PsAF in elderly and younger patients.